Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Cohance Lifesciences has informed that the United States Food and Drug Administration (USFDA) inspected the Company’s formulation (FDF) plant located at Shamshabad, Telangana, from 27 August to 4 September 2026. The inspection concluded with the issuance of a Form FDA 483 containing four observations. The Company has initiated appropriate corrective and preventive actions (CAPA) and will submit its response within the stipulated timeline. The Company remains committed to quality and regulatory compliance.
The above information is a part of company’s filings submitted to BSE.
